Baseline characteristics and discharge medications
| Characteristic | n | Study population n=100 879 |
| Sex: Male | 100 879 | 69 634 (69.0%) |
| Female | 31 245 (31.0%) | |
| Follow-up (years) | 100 879 | 3.6 (1.6–5.8) |
| Age | 100 879 | 68.0 (60.0–76.0) |
| Admission year: 2006 | 100 879 | 5576 (5.5%) |
| 2007 | 11 972 (11.9%) | |
| 2008 | 11 942 (11.8%) | |
| 2009 | 11 756 (11.7%) | |
| 2010 | 12 037 (11.9%) | |
| 2011 | 12 180 (12.1%) | |
| 2012 | 12 612 (12.5%) | |
| 2013 | 12 056 (12.0%) | |
| 2014 | 10 748 (10.7%) | |
| Smoking | 99 283 | 24 684 (24.9%) |
| Age ≥65 | 100 879 | 62 469 (61.9%) |
| Multivessel disease | 100 879 | 52 046 (51.6%) |
| Chronic kidney disease | 100 879 | 21 532 (21.3%) |
| Diabetes mellitus | 100 879 | 18 906 (18.7%) |
| Prior myocardial infarction | 100 879 | 18 426 (18.3%) |
| Prior major bleeding | 100 879 | 7369 (7.3%) |
| Previous stroke | 100 879 | 5439 (5.4%) |
| Previous atrial fibrillation | 100 879 | 6655 (6.6%) |
| Previous heart failure | 100 879 | 5153 (5.1%) |
| Previous angina pectoris | 100 879 | 15 376 (15.2%) |
| Previous peripheral arterial disease | 100 879 | 2448 (2.4%) |
| Hypertension | 100 879 | 51 379 (50.9%) |
| Hyperlipidaemia | 100 862 | 94 863 (94.1%) |
| Aspirin at discharge | 100 403 | 95 093 (94.7%) |
| P2Y12 inhibitor at discharge | 100 658 | 86 990 (86.4%) |
| Oral anticoagulation at discharge | 100 262 | 6404 (6.4%) |
| Statin at discharge | 100 655 | 93 570 (93%) |
| Beta blocker at discharge | 100 660 | 90 233 (89.6%) |
| Calcium blocker at discharge | 100 656 | 15 042 (14.9%) |
| ACE inhibitor at discharge | 100 607 | 63 858 (63.5%) |
| Angiotensin II receptor blocker at discharge | 99 083 | 15 208 (15.3%) |